Beta-Blocker Withdrawal in Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence (BRILLIANT)

Phase 2

Recruiting

• Conditions: Heart failure with preserved ejection fraction

• Registration Number: JPRN-jRCT1031210030
• Lead Sponsor: Obokata Masaru

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-09
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1) Age equal to or more than 20 years old
2) Patients with established HFpEF or subjects who are suspected of HFpEF
3) Subjects who are treated with a pre-specified minimum dose of beta-blockers
5) Subjects who are able to keep cycle ergometry
exercise (0 watts) for more than 30 seconds
6) Patients who give written consent to participate in this study

Exclusion Criteria

1) Patients with mimic HFpEF:
More than mild aortic or mitral valve stenosis, more than moderate aortic or mitral valve regurgitation, history of left ventricular ejection fraction less than 40%, non-group II pulmonary hypertension, hypertrophic cardiomyopathy, cardiac sarcoidosis, constrictive pericardititis
2) Patients with comorbidities contraindicated for exercise testing:
acute decompensated heart failure, acute coronary syndrome, severe coronary artery disease
3) Patients who are expected to have disadvantages in discontinuing beta-blockers:
History of old myocardial infarction, presence of obvious myocardial ischemia, appearance of new wall motion abnormality during exercise, history of hospitalization due to tachyarrhythmia within 6 months, Basedow's disease
4) Patients who cannot exercise their legs due to
abnormalities in joints, muscles, etc.
4) Patients who are judged to be unsuitable for th
e study by the investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified